Cargando…

Human papillomavirus‐based screening at extended intervals missed fewer cervical precancers than cytology in the HPV For Cervical Cancer (HPV FOCAL) trial

While cervix screening using cytology is recommended at 2‐ to 3‐year intervals, given the increased sensitivity of human papillomavirus (HPV)‐based screening to detect precancer, HPV‐based screening is recommended every 4‐ to 5‐years. As organized cervix screening programs transition from cytology t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gottschlich, Anna, Gondara, Lovedeep, Smith, Laurie W., Cook, Darrel, Martin, Ruth Elwood, Lee, Marette, Peacock, Stuart, Proctor, Lily, Stuart, Gavin, Krajden, Mel, Franco, Eduardo L., van Niekerk, Dirk, Ogilvie, Gina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2022
Materias:	Cancer Therapy and Prevention
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9336650/ https://www.ncbi.nlm.nih.gov/pubmed/35460070 http://dx.doi.org/10.1002/ijc.34039

Ejemplares similares

Willingness to Self-Collect a Sample for HPV-Based Cervical Cancer Screening in a Well-Screened Cohort: HPV FOCAL Survey Results
por: Lesack, Anne, et al.
Publicado: (2022)

Disease detection and resource use in the safety and control arms of the HPV FOCAL cervical cancer screening trial
por: Coldman, Andrew J, et al.
Publicado: (2016)

Women’s acceptability of and experience with primary human papillomavirus testing for cervix screening: HPV FOCAL trial cross-sectional online survey results
por: Smith, Laurie W, et al.
Publicado: (2021)

Colposcopy referral rates post-introduction of primary screening with human papillomavirus testing: evidence from a large British Columbia cohort study
por: Gottschlich, Anna, et al.
Publicado: (2023)

Cost‐effectiveness analysis of primary human papillomavirus testing in cervical cancer screening: Results from the HPV FOCAL Trial
por: Cromwell, Ian, et al.
Publicado: (2021)

A randomized controlled trial of Human Papillomavirus (HPV) testing for cervical cancer screening: trial design and preliminary results (HPV FOCAL Trial)
por: Ogilvie, Gina S, et al.
Publicado: (2010)

Evaluation of a validated methylation triage signature for human papillomavirus positive women in the HPV FOCAL cervical cancer screening trial
por: Cook, Darrel A., et al.
Publicado: (2018)

Comparison of the Roche cobas® 4800 and Digene Hybrid Capture® 2 HPV tests for primary cervical cancer screening in the HPV FOCAL trial
por: Cook, Darrel A., et al.
Publicado: (2015)

Primary cervical cancer screening with HPV testing compared with liquid-based cytology: results of round 1 of a randomised controlled trial – the HPV FOCAL Study
por: Ogilvie, G S, et al.
Publicado: (2012)

Genetic and Epigenetic Variations of HPV52 in Cervical Precancer
por: Bee, Katharine J., et al.
Publicado: (2021)

Initial results of population based cervical cancer screening program using HPV testing in one million Turkish women
por: Gultekin, Murat, et al.
Publicado: (2017)

Radiosensitization approaches for HPV‐positive and HPV‐negative head and neck squamous carcinomas
por: Dok, Rüveyda, et al.
Publicado: (2019)

Reliable identification of women with CIN3+ using hrHPV genotyping and methylation markers in a cytology‐screened referral population
por: Leeman, Annemiek, et al.
Publicado: (2018)

Clinical validation of p16/Ki‐67 dual‐stained cytology triage of HPV‐positive women: Results from the IMPACT trial
por: Wright, Thomas C., et al.
Publicado: (2021)

Absolute risks of cervical precancer among women who fulfill exiting guidelines based on HPV and cytology cotesting
por: Landy, Rebecca, et al.
Publicado: (2019)

Telomere length in cervical exfoliated cells, interaction with HPV genotype, and cervical cancer occurrence among high‐risk HPV‐positive women
por: Chen, Xiaojun, et al.
Publicado: (2019)

A comparison of methylation levels in HPV18, HPV31 and HPV33 genomes reveals similar associations with cervical precancers()
por: Vasiljević, Nataša, et al.
Publicado: (2014)

Effectiveness of the AS04‐adjuvanted HPV‐16/18 vaccine in reducing oropharyngeal HPV infections in young females—Results from a community‐randomized trial
por: Lehtinen, Matti, et al.
Publicado: (2019)

Searching HPV genome for methylation sites involved in molecular progression to cervical precancer
por: Kottaridi, Christine, et al.
Publicado: (2019)

Prevalence of high‐risk human papillomavirus after HPV‐vaccination in Denmark
por: Lynge, Elsebeth, et al.
Publicado: (2020)

Risk Factors for Cervical Precancer and Cancer in HIV-Infected, HPV-Positive Rwandan Women
por: Anastos, Kathryn, et al.
Publicado: (2010)

Cervical cancer risk in HPV‐positive women after a negative FAM19A4/mir124‐2 methylation test: A post hoc analysis in the POBASCAM trial with 14 year follow‐up
por: De Strooper, Lise M.A., et al.
Publicado: (2018)

Risk of cervical precancer among HPV–negative women in the Netherlands and its association with previous HPV and cytology results: A follow-up analysis of a randomized screening study
por: Inturrisi, Federica, et al.
Publicado: (2022)

Methylation estimates the risk of precancer in HPV-infected women with discrepant results between cytology and HPV16/18 genotyping
por: Hernández-López, Rubí, et al.
Publicado: (2019)

The precision prevention and therapy of HPV‐related cervical cancer: new concepts and clinical implications
por: Hu, Zheng, et al.
Publicado: (2018)

Now or later: Health impacts of delaying single‐dose HPV vaccine implementation in a high‐burden setting
por: Burger, Emily A., et al.
Publicado: (2022)

HPV-specific risk assessment of cervical cytological abnormalities
por: Zhong, Guanglei, et al.
Publicado: (2021)

The distribution and pathogenic risk of non‐9‐valent vaccine covered HPV subtypes in cervical lesions
por: Ma, Mingjun, et al.
Publicado: (2022)

Single Nucleotide Polymorphisms in the PRDX3 and RPS19 and Risk of HPV Persistence and Cervical Precancer/Cancer
por: Safaeian, Mahboobeh, et al.
Publicado: (2012)

High prevalence of HPV in non-cervical sites of women with abnormal cervical cytology
por: Crawford, Robin, et al.
Publicado: (2011)

At what age should the Uyghur minority initiate cervical cancer screening if screened using careHPV
por: Abulizi, Guzhalinuer, et al.
Publicado: (2021)

Efficacy of careHPV™ human papillomavirus screening versus conventional cytology tests for the detection of precancerous and cancerous cervical lesions among women living with HIV‐1 in Lao People's Democratic Republic
por: Paboriboune, Phimpha, et al.
Publicado: (2022)

Women with a positive high-risk human papillomavirus (HPV) test remain at increased risk of HPV infection and cervical precancer ≥15 years later
por: Inturrisi, Federica, et al.
Publicado: (2022)

Awareness and knowledge of Human Papillomavirus (HPV), HPV‐related cancers, and HPV vaccines in an uninsured adult clinic population
por: Radecki Breitkopf, Carmen, et al.
Publicado: (2016)

Detecting cervical precancer and reaching underscreened women by using HPV testing on self samples: updated meta-analyses
por: Arbyn, Marc, et al.
Publicado: (2018)

HPV testing of self-samples: Influence of collection and sample handling procedures on clinical accuracy to detect cervical precancer
por: Arbyn, Marc, et al.
Publicado: (2022)

Roles of extended human papillomavirus genotyping and multiple infections in early detection of cervical precancer and cancer and HPV vaccination
por: Song, Fangbin, et al.
Publicado: (2022)

Cervical precancer screening with HPV DNA testing and mobile colposcopy in women with sickle cell disease in Accra, Ghana
por: Dei-Adomakoh, Yvonne, et al.
Publicado: (2023)

Cervical cancer screening in a low‐resource setting: a pilot study on an HPV‐based screen‐and‐treat approach
por: Kunckler, Margot, et al.
Publicado: (2017)

HPV‐vaccination and cancer cervical screening in 53 WHO European Countries: An update on prevention programs according to income level
por: Altobelli, Emma, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_m4ksoggnd3q9f59ccco345b9an